Intellia Therapeutics, Inc.NTLA stock score: 33/100
$9.52 · -2.56% · Scored Nov 19, 2026
- Technical
- 26
- Fundamental
- 35
- News
- 54
The reading
Intellia Therapeutics (NTLA) scores 33 out of 100, which reads bearish, higher than 8% of Healthcare stocks and 9% of the 4,118 US stocks we score.
The composite weights fundamentals 80% and technicals 20%: fundamentals read 35, technicals 26.
Among the fundamentals, Quick Ratio at 100 and Price Target at 100 score highest, while Earnings Profitability (Quarterly) at 0 weighs the most against it.
On the daily chart, trend-following indicators average 15 and contrarian oscillators 70 — a split worth reading before trusting the technical total.
News sentiment is neutral at 54; it is shown, not counted in the composite.
Since Aug 22, 2026 the composite has ranged from 31 to 43, and it is down 7 points over the period.
About Intellia Therapeutics
Intellia Therapeutics (NTLA) is a genome editing company that develops medicines using CRISPR technology delivered directly into the body. Its approach packages CRISPR components in lipid nanoparticles that travel mainly to the liver, where they permanently switch off a disease-causing gene with a single treatment. Its most advanced candidate, lonvoguran ziclumeran, known as lonvo-z, is designed to prevent swelling attacks in hereditary angioedema by inactivating the KLKB1 gene, and it has produced positive late-stage trial results, which Intellia is using to seek U.S. approval. Its second major program, nexiguran ziclumeran, or nex-z, targets transthyretin amyloidosis with cardiomyopathy or polyneuropathy and is in late-stage trials in collaboration with Regeneron. Intellia has little revenue today, mainly from collaborations, and funds development with cash raised from investors.
In hereditary angioedema, Intellia would compete with Takeda, CSL Behring, BioCryst, Ionis and KalVista, while in transthyretin amyloidosis it faces Alnylam, Pfizer, BridgeBio and AstraZeneca. Among gene editing companies, it competes with CRISPR Therapeutics and Beam Therapeutics. Its edge rests on clinical data supporting one-time treatment, its delivery technology and patents. Investors who follow NTLA stock tend to watch the approval process and launch preparations for lonvo-z. Safety findings and enrollment in the nex-z trials are closely followed. Pricing, reimbursement, manufacturing and cash runway are other factors.
What’s driving the score
The strongest and weakest of the scorers that count toward NTLA’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
35Pulling it up
- Quick Ratio100
Quick ratio measures a company's ability to meet short-term obligations with liquid assets.
- Price Target100
Price target score compares the current stock price to analyst consensus targets.
Current assets divided by current liabilities: the ability to pay short-term bills.
Holding it back
Earnings Profitability (Quarterly) measures recent profitability using trailing 12-month quarterly data.
Absolute profitability: whether the company is profitable, its net margin against the sector range, and how consistently it has been profitable over three years.
Price-to-Sales ratio compares market capitalization to annual revenue.
36 weighted scorers; 3 had no data today and are left out rather than counted as zero.
Technical · daily
22Pulling it up
Bollinger Bands (50-period) measure where price sits between bands two standard deviations around its 50-period average.
Bollinger Bands (20-period) plot standard deviations above and below a moving average.
Williams %R (28-period) places the close within the last 28 periods' high-low range.
Holding it back
Ichimoku Cloud is a comprehensive indicator showing support/resistance, trend direction, and momentum.
Simple Moving Average (20-period) represents a key short to intermediate-term trend indicator.
- VWAP0
Volume Weighted Average Price (VWAP) shows the average price weighted by volume.
61 weighted scorers; 4 had no data today and are left out rather than counted as zero.
News · shown, not counted
- Global News
- 54
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 33 | 1 |
| Daily | 22 | 3 |
| Weekly | 22 | 2 |
| Monthly | 33 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Nov 19, 2026 | 33 |
| Nov 18, 2026 | 34 |
| Nov 17, 2026 | 34 |
| Nov 16, 2026 | 34 |
| Nov 15, 2026 | 34 |
| Nov 14, 2026 | 34 |
| Nov 13, 2026 | 34 |
| Nov 12, 2026 | 32 |
| Nov 11, 2026 | 34 |
| Nov 10, 2026 | 33 |
| Nov 9, 2026 | 36 |
| Nov 8, 2026 | 33 |
| Nov 7, 2026 | 33 |
| Nov 6, 2026 | 33 |
| Nov 5, 2026 | 32 |
| Nov 4, 2026 | 39 |
| Nov 3, 2026 | 37 |
| Nov 2, 2026 | 36 |
| Nov 1, 2026 | 39 |
| Oct 31, 2026 | 39 |
| Oct 30, 2026 | 39 |
| Oct 29, 2026 | 43 |
| Oct 28, 2026 | 41 |
| Oct 27, 2026 | 37 |
| Oct 26, 2026 | 33 |
| Oct 25, 2026 | 32 |
| Oct 24, 2026 | 32 |
| Oct 23, 2026 | 31 |
| Oct 22, 2026 | 31 |
| Oct 21, 2026 | 33 |
| Oct 20, 2026 | 34 |
| Oct 19, 2026 | 32 |
| Oct 18, 2026 | 32 |
| Oct 17, 2026 | 32 |
| Oct 16, 2026 | 32 |
| Oct 15, 2026 | 32 |
| Oct 14, 2026 | 32 |
| Oct 13, 2026 | 34 |
| Oct 12, 2026 | 39 |
| Oct 11, 2026 | 40 |
| Oct 10, 2026 | 40 |
| Oct 9, 2026 | 40 |
| Oct 8, 2026 | 38 |
| Oct 7, 2026 | 33 |
| Oct 6, 2026 | 38 |
| Oct 5, 2026 | 39 |
| Oct 4, 2026 | 37 |
| Oct 3, 2026 | 37 |
| Oct 2, 2026 | 38 |
| Oct 1, 2026 | 36 |
| Sep 30, 2026 | 36 |
| Sep 29, 2026 | 34 |
| Sep 28, 2026 | 33 |
| Sep 27, 2026 | 34 |
| Sep 26, 2026 | 34 |
| Sep 25, 2026 | 34 |
| Sep 24, 2026 | 36 |
| Sep 23, 2026 | 37 |
| Sep 22, 2026 | 39 |
| Sep 21, 2026 | 37 |
| Sep 20, 2026 | 35 |
| Sep 19, 2026 | 35 |
| Sep 18, 2026 | 35 |
| Sep 17, 2026 | 37 |
| Sep 16, 2026 | 33 |
| Sep 15, 2026 | 32 |
| Sep 14, 2026 | 33 |
| Sep 13, 2026 | 34 |
| Sep 12, 2026 | 34 |
| Sep 11, 2026 | 34 |
| Sep 10, 2026 | 33 |
| Sep 9, 2026 | 35 |
| Sep 8, 2026 | 39 |
| Sep 7, 2026 | 39 |
| Sep 6, 2026 | 39 |
| Sep 5, 2026 | 39 |
| Sep 4, 2026 | 38 |
| Sep 3, 2026 | 38 |
| Sep 2, 2026 | 39 |
| Sep 1, 2026 | 38 |
| Aug 31, 2026 | 38 |
| Aug 30, 2026 | 39 |
| Aug 29, 2026 | 40 |
| Aug 28, 2026 | 39 |
| Aug 27, 2026 | 41 |
| Aug 26, 2026 | 41 |
| Aug 25, 2026 | 42 |
| Aug 24, 2026 | 37 |
| Aug 23, 2026 | 40 |
| Aug 22, 2026 | 40 |
Key facts
- Market cap
- $1.3B
- Sector
- Healthcare
- Industry
- Biotechnology
- Beta
- 1.82
- Risk grade (1–10)
- 8
- Next earnings
- Nov 5, 2026
Biotechnology peers
| Company | Market cap | Score |
|---|---|---|
| IMCR Immunocore Holdings | $1.4B | 51 |
| TYRA Tyra Biosciences | $1.4B | 31 |
| NUVB Nuvation Bio | $1.3B | 40 |
| INVA Innoviva | $1.3B | 63 |
| LBRX LB Pharmaceuticals | $1.3B | 41 |
| OCUL Ocular Therapeutix | $1.3B | 38 |
Questions
What is NTLA's stock rating today?
NTLA scores 33/100 (Bearish) as of Nov 19, 2026: technical 26, fundamental 35, and news sentiment 54, which is shown but not counted. Scores are recomputed every night.
What does Intellia Therapeutics do?
Intellia Therapeutics (NTLA) is a genome editing company that develops medicines using CRISPR technology delivered directly into the body. Its approach packages CRISPR components in lipid nanoparticles that travel mainly to the liver, where they permanently switch off a disease-causing gene with a single treatment.
Is NTLA stock a buy?
The score is not a buy or sell recommendation. A 33 says the technical and fundamental signals we measure lean bearish today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the NTLA score calculated?
97 weighted scorers feed it today: 36 fundamental, scored against Healthcare ranges, and 61 technical on the daily chart, with 4 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.
Embed this score
A badge for a blog post, newsletter or README. It updates every night and links back here. More badges
HTML
<a href="https://stocksscores.com/stocks/ntla/"><img src="https://stocksscores.com/stocks/ntla/badge.svg" alt="NTLA stock score" height="20"></a>
Markdown
[](https://stocksscores.com/stocks/ntla/)